Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy [Yahoo! Finance]
Lexaria Bioscience Corp. (LEXX)
Company Research
Source: Yahoo! Finance
The Company has received a new granted patent in Lexaria's patent family #21: Compositions and Methods for Treating Hypertension. This is the Company's third granted US patent in this patent family. As Lexaria has repeatedly demonstrated, DehydraTECH-processed cannabidiol ("CBD") has evidenced an ability to lower blood pressure in both acute dosing in hypertension as well as over a 5-week study duration . This patent will expire in 2042 if not extended. The Company has also received a new granted patent in Lexaria's patent family #24: Compositions and Methods for Treating Epilepsy . This is the Company's third granted US patent in this patent family. This patent complements earlier research that discovered DehydraTECH-CBD was capable of mitigating epileptic seizures in rodents, and was also absorbed into the bloodstream more effectively than the commercially available cannabinoid-based anti-seizure medication, Epidiolex®. This patent will expire in 2042 if not extended. With the
Show less
Read more
Impact Snapshot
Event Time:
LEXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEXX alerts
High impacting Lexaria Bioscience Corp. news events
Weekly update
A roundup of the hottest topics
LEXX
News
- Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study [Yahoo! Finance]Yahoo! Finance
- Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human StudyAccesswire
- Dosing Continues in Lexaria’s Second GLP-1 Human Pilot StudyAccesswire
- Lexaria Awards Contract For Third GLP-1 Human Pilot Study [Yahoo! Finance]Yahoo! Finance
- Lexaria Awards Contract For Third GLP-1 Human Pilot StudyAccesswire
LEXX
Sec Filings
- 6/12/24 - Form EFFECT
- 6/11/24 - Form 424B3
- 6/3/24 - Form S-1
- LEXX's page on the SEC website